No Data
Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa
U.S.-listed shares of Ascendis Pharma (ASND) gained 7% to $101.82, after the Danish biotech reported Q2 results that beat estimates, helped by a surge in sales of growth hormone drug Skytrofa. ASND po
Ascendis Pharma shares are trading higher after the company reported Q2 sales results were higher year over year.
Ascendis Pharma shares are trading higher after the company reported Q2 sales results were higher year over year.
Ascendis Pharma Is Maintained at Overweight by Morgan Stanley
Ascendis Pharma Is Maintained at Overweight by Morgan Stanley
Ascendis Pharma Price Target Cut to $148.00/Share From $152.00 by Morgan Stanley
Ascendis Pharma Price Target Cut to $148.00/Share From $152.00 by Morgan Stanley
Ascendis Pharma Is Maintained at Outperform by Oppenheimer
Ascendis Pharma Is Maintained at Outperform by Oppenheimer
Ascendis Pharma Price Target Cut to $144.00/Share From $154.00 by Oppenheimer
Ascendis Pharma Price Target Cut to $144.00/Share From $154.00 by Oppenheimer
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $148
Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $152 to $148.
Oppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $144
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma with a Outperform and lowers the price target from $154 to $144.
Ascendis Pharma Is Maintained at Outperform by SVB Leerink
Ascendis Pharma Is Maintained at Outperform by SVB Leerink
Ascendis Pharma Price Target Cut to $168.00/Share From $174.00 by SVB Leerink
Ascendis Pharma Price Target Cut to $168.00/Share From $174.00 by SVB Leerink
Loading...